Peptide Initiative

Peptides · Peptide comparison

Lentinan vs Thymosin Alpha-1

Mushroom-derived β-glucan polysaccharide with potent immunomodulatory and antitumor properties approved for cancer therapy in Japan

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeLentinan2–2 mgThymosin Alpha-11.6–1.6 mg
FrequencyLentinanOnce weeklyThymosin Alpha-1Twice weekly
AdministrationLentinanIntravenous infusionThymosin Alpha-1Subcutaneous injection
Cycle lengthLentinan8-12 weeksThymosin Alpha-18-12 weeks
Onset speedLentinanModerate (1-2 weeks)Thymosin Alpha-1Moderate (1-2 weeks)
Evidence levelLentinanModerate human trials (Phase 1-2)Thymosin Alpha-1Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Immune

Lentinan95%
Thymosin Alpha-1No recorded rating

Healing & Recovery

Lentinan70%
Thymosin Alpha-1No recorded rating

Anti-Aging

Lentinan40%
Thymosin Alpha-1No recorded rating

Immune Activation

LentinanNo recorded rating
Thymosin Alpha-195%

Infection Fighting

LentinanNo recorded rating
Thymosin Alpha-192%

Immune Balance

LentinanNo recorded rating
Thymosin Alpha-188%

Technical data

Compound specifications

Lentinan

Molecular formula
(C6H10O5)n (repeating glucose units)
Molecular weight
~500,000 g/mol (varies by preparation)
Half-life
Approximately 15-30 minutes (IV administration)
Bioavailability
100% (intravenous administration)
CAS number
37339-90-5

Thymosin Alpha-1

Molecular formula
C129H215N33O55
Molecular weight
3108.32 g/mol
Half-life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS number
62304-98-7

Protocols

Dosing compared

Lentinan

Intravenous

  • 1 mg per doseTwice weekly · Continued alongside chemotherapy cyclesEstablished clinical regimen in Japan (approved 1985 as a biological response modifier for gastric cancer): 1 mg IV twice weekly combined with chemotherapy such as tegafur or 5-FU [1][6].
  • 2 mg per doseOnce weekly (some protocols every 2-3 weeks) · Continued alongside chemotherapy cyclesAlternative approved IV schedule: 2 mg once weekly; more recent protocols give 2 mg every 2-3 weeks. Used as an immunomodulatory adjunct to S-1/tegafur-based chemotherapy in advanced/recurrent gastric cancer [1][6].

Thymosin Alpha-1

Subcutaneous injection

  • 1.6 mgTwice weekly (3-4 days apart) · 6-12 monthsEstablished clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
  • 1.6 mg daily, then 1.6 mg twice weeklyDaily for an initial loading period, then twice weekly · 12+ weeksThe schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].

Applications

Best suited for

Lentinan

Advanced Gastric Cancer
Lentinan's primary and best-studied indication is as an adjuvant to chemotherapy for unresectable and recurrent gastric cancer. A multi-institutional randomized trial demonstrated significantly extended survival (297 vs 199 days median) and dramatically improved one-year survival rates (49.1% vs 0%) [1].
Lung Cancer Adjuvant Therapy
A 12-year review of clinical studies in China demonstrated that lentinan combined with chemotherapy improves outcomes in lung cancer patients, [9] with a meta-analysis confirming increased chemotherapy efficacy and improved quality of life [10].
Cancer Patients Needing Quality of Life Support
Clinical trials consistently show lentinan improves patient quality of life during cancer treatment, particularly appetite and sleep quality, while reducing the toxic side effects of chemotherapy and enabling treatment continuity [1][10].
Immunocompromised Patients
Phase 1/2 clinical trials in HIV-positive patients have explored lentinan's ability to enhance immune function when combined with antiretroviral therapy, though this application remains investigational [7][8].

Thymosin Alpha-1

Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.

Safety profile

Side effects

Lentinan

Common

  • Fever and chills
  • Infusion site discomfort
  • Transient fatigue
  • Nausea

Uncommon

  • Chest tightness or back pain
  • Granulocytopenia

Serious

  • Anaphylaxis
  • Severe allergic reaction / Anaphylaxis

Thymosin Alpha-1

Common

  • Injection site reactions

Uncommon

  • Mild fatigue
  • Flu-like symptoms
  • Mild fever
  • Lymph node awareness

Serious

  • Allergic reaction

Research status

Safety & evidence

Lentinan

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Lentinan is a beta-1,3-glucan polysaccharide (not a true peptide) extracted from shiitake mushroom with a 40-year safety record in Japanese and Asian oncology practice. Parenteral lentinan shows excellent tolerability as an immune adjuvant [7] with minimal systemic toxicity—hepatotoxicity and nephrotoxicity are essentially absent in clinical use. Fever and localized reactions at injection sites (5-15% of patients) are the documented side effects. The compound works through pattern recognition receptors (Dectin-1, TLR-2) to enhance NK cell and macrophage function without inducing autoimmunity [2].

Contraindications

  • Known hypersensitivity to lentinan or shiitake mushroom components
  • History of anaphylactic reactions to β-glucan polysaccharides
  • Severe immunosuppression where immune activation is contraindicated
  • Active autoimmune disease in flare (immune stimulation could worsen)

Thymosin Alpha-1

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
Safety overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Contraindications

  • Organ transplant recipients on immunosuppressants
  • Active autoimmune disease flares
  • Known allergy to thymosin peptides
  • Pregnancy or breastfeeding
  • Children under 18 without medical supervision

Decision guide

Which is right for you?

Lentinan

Choose Lentinan if…

  • Adjunctive cancer therapy (especially gastric cancer)
  • Immune system enhancement during chemotherapy
  • Improving quality of life for cancer patients
  • Supporting immune function in immunocompromised individuals

Thymosin Alpha-1

Choose Thymosin Alpha-1 if…

  • Immune system strengthening
  • Chronic infection support
  • Cancer adjunct therapy
  • Healthy aging immune support